Back to Search
Start Over
Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation
- Source :
- Healthcare, Healthcare, Vol 8, Iss 404, p 404 (2020), Volume 8, Issue 4
- Publication Year :
- 2020
-
Abstract
- (1) Aim: The aim of this study was to assess the preferences of oral anticoagulants (OA) in patients diagnosed with deep vein thrombosis (DVT) of lower limbs or non-valvular atrial fibrillation (AF) requiring anticoagulation for medium/long term. (2) Materials and methods: the study included consecutive patients admitted with a diagnosis of either acute DVT of lower limbs (without signs of pulmonary embolism) or non-valvular AF who required oral anticoagulation, in a time frame of 18 months from January 2017 until June 2018. The following data were recorded: demographic variables, comorbidities (ischemic heart disease, arterial hypertension, heart failure, stroke, peripheral artery disease, diabetes mellitus, obesity), type and dose of OA (acenocoumarol, dabigatran, apixaban, rivaroxaban), complications due to the use of OA. (3) Results: AF patients were older and had considerably more cardiovascular comorbidities than DVT patients. Vitamin K antagonists (VKA) were more likely to be administered in patients with AF, as they had indication for indefinite anticoagulation. VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes compared with DVT patients. Moreover, complications related to OA use were more frequent in the VKA group. Almost half of patients with acute DVT (48.5%) were treated with direct OA (DOAC) rather than VKA, and only a quarter of AF patients (24.8%) were treated with DOACs.
- Subjects :
- medicine.medical_specialty
anticoagulant choice
Leadership and Management
Deep vein
lcsh:Medicine
Health Informatics
030204 cardiovascular system & hematology
direct oral anticoagulants
Article
deep vein thrombosis
Dabigatran
03 medical and health sciences
0302 clinical medicine
Health Information Management
Internal medicine
medicine
atrial fibrillation
030212 general & internal medicine
cardiovascular diseases
Stroke
Rivaroxaban
business.industry
Health Policy
lcsh:R
Atrial fibrillation
medicine.disease
Thrombosis
vitamin K antagonists
medicine.anatomical_structure
Heart failure
Cardiology
Apixaban
business
medicine.drug
Subjects
Details
- ISSN :
- 22279032
- Volume :
- 8
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Healthcare (Basel, Switzerland)
- Accession number :
- edsair.doi.dedup.....33e44042d39004c44f2158abf00de89f